Fungal infections kill an estimated 1.5 million people annually — more than malaria and comparable to tuberculosis — yet fungal diseases receive a fraction of the research funding and public attention devoted to bacterial and viral infections (Bongomin et al., 2017, Journal of Fungi). The antifungal drug arsenal is remarkably small — only four major classes of antifungal drugs exist, compared to dozens of antibiotic classes — and resistance is emerging in alarming patterns. Understanding how antifungal medications work requires understanding the unique biology of fungi, the pharmacological targets exploited by each drug class, and the resistance mechanisms that threaten our already-limited therapeutic options.
Fungal biology: why fungi are hard to treat
Fungi are eukaryotes — they share fundamental cellular biology with human cells: fungi have membrane-bound nuclei, 80S ribosomes, mitochondria, and eukaryotic cell membranes; this shared biology means that many targets exploited by antibacterial antibiotics (70S ribosomes, peptidoglycan, bacterial-specific enzymes) do not exist in fungi; the key differences between fungal and human cells — exploited by antifungal drugs — include: ergosterol (the predominant sterol in fungal cell membranes, analogous to cholesterol in human membranes), the fungal cell wall (chitin, β-glucan, and mannan — structures absent from human cells), and unique aspects of nucleotide synthesis; and the limited number of exploitable differences explains why there are so few antifungal drug classes — and why many antifungals have significant toxicity (they affect human cells to varying degrees) (Perfect, 2017, Nature Reviews Drug Discovery).
Azoles: inhibiting ergosterol synthesis
Azoles (fluconazole, itraconazole, voriconazole, posaconazole, isavuconazole) are the most widely used antifungal class: mechanism: azoles inhibit lanosterol 14α-demethylase (CYP51/Erg11) — a cytochrome P450 enzyme required for converting lanosterol to ergosterol; ergosterol depletion → altered membrane fluidity, permeability, and function → impaired fungal growth; and toxic sterol intermediates (14-methylated sterols) accumulate → direct membrane toxicity. Fluconazole is the most commonly prescribed antifungal globally — used for Candida infections, cryptococcal meningitis (in HIV/AIDS), and various other mycoses. Voriconazole is the drug of choice for invasive aspergillosis (Lepesheva & Waterman, 2007, Molecular and Cellular Endocrinology).
Polyenes: binding ergosterol directly
Amphotericin B — the prototypical polyene antifungal — remains one of the most important antifungal drugs despite its toxicity: mechanism: amphotericin B binds directly to ergosterol in the fungal membrane → forms transmembrane pores → ion leakage → cell death; amphotericin B has the broadest spectrum of any antifungal — active against most Candida species, Aspergillus, Cryptococcus, Mucorales (mucormycosis), and endemic mycoses; toxicity: conventional amphotericin B deoxycholate causes significant nephrotoxicity (renal tubular damage from drug binding to cholesterol in renal cell membranes), infusion-related reactions (fever, chills, rigors), electrolyte wasting (potassium and magnesium), and anemia; and lipid formulations (liposomal amphotericin B, amphotericin B lipid complex) preferentially deliver drug to fungal cells → reduced nephrotoxicity → improved therapeutic index (Hamill, 2013, Drugs).
Echinocandins: targeting the fungal cell wall
Echinocandins (caspofungin, micafungin, anidulafungin) represent the newest antifungal class: mechanism: echinocandins inhibit β-1,3-glucan synthase — the enzyme complex that synthesizes β-1,3-glucan (a major structural polysaccharide of the fungal cell wall); β-glucan depletion → cell wall instability → osmotic stress → cell lysis; because humans lack β-glucan in their cells, echinocandins have an excellent safety profile (the most favorable toxicity profile of any antifungal class); limitations: echinocandins are only available intravenously (not absorbed orally), have limited activity against Cryptococcus and Mucorales, and some Candida species (C. parapsilosis) are intrinsically less susceptible (Perlin, 2015, Clinical Infectious Diseases).
Antifungal resistance: the growing crisis
Candida auris
Candida auris — first identified in Japan in 2009 — has emerged as a global multidrug-resistant pathogen: often resistant to fluconazole (>90% of isolates), some strains resistant to amphotericin B, and emerging resistance to echinocandins; C. auris persists on hospital surfaces for weeks → causing healthcare-associated outbreaks; mortality rates for invasive C. auris infections approach 30-60%; and the CDC has classified C. auris as an "urgent threat" (Lockhart et al., 2017, Clinical Infectious Diseases).
Aspergillus fumigatus azole resistance
Azole-resistant Aspergillus fumigatus has been detected globally: agricultural azole fungicide use (environmental exposure) is a major driver — azole fungicides used in agriculture share the same mechanism as medical azoles (CYP51 inhibition); resistant isolates carry mutations in the cyp51A gene (TR₃₄/L98H, TR₄₆/Y121F/T289A); and patients infected with azole-resistant A. fumigatus have significantly higher mortality than those with susceptible strains (Chowdhary et al., 2017, PLOS Pathogens).
Antifungal medicines protect us against an entire kingdom of life that most people never think about — until a fungal infection becomes invasive and life-threatening. With only four drug classes available and resistance emerging on multiple fronts, antifungal drug development is one of the most urgent priorities in infectious disease research.
Flucytosine (5-FC): antimetabolite therapy
Flucytosine (5-fluorocytosine) represents the fourth antifungal class — an antimetabolite: mechanism: 5-FC enters fungal cells via cytosine permease → converted to 5-fluorouracil (5-FU) by cytosine deaminase (fungi express this enzyme; human cells do not) → 5-FU interferes with: RNA synthesis (incorporation into RNA → aberrant protein synthesis) and DNA synthesis (inhibition of thymidylate synthase); 5-FC is rarely used as monotherapy (rapid resistance development) — typically combined with amphotericin B for cryptococcal meningitis; and the sequential conversion — 5-FC → 5-FU — creates selectivity because human cells lack significant cytosine deaminase activity (Vermes et al., 2000, Journal of Antimicrobial Chemotherapy).
Fungal infections and immunocompromised patients
The most devastating fungal infections occur in immunocompromised patients: invasive aspergillosis — affects patients with prolonged neutropenia (chemotherapy, stem cell transplant) — mortality 30-50% despite treatment; Pneumocystis pneumonia — affects HIV/AIDS patients with CD4 < 200 (prevented by trimethoprim-sulfamethoxazole prophylaxis); cryptococcal meningoencephalitis — affects approximately 220,000 HIV/AIDS patients annually, causing approximately 181,000 deaths globally (Rajasingham et al., 2017, Lancet Infectious Diseases); invasive candidiasis — affects ICU patients, surgical patients, patients with central venous catheters — mortality 35-60%; and mucormycosis (zygomycosis) — affects patients with uncontrolled diabetes, ketoacidosis, hematologic malignancy, or solid organ transplant — rapidly destructive rhinocerebral, pulmonary, or disseminated disease.
Dermatophyte infections: the common fungal diseases
While invasive mycoses get the most medical attention, dermatophyte infections are by far the most common fungal diseases: tinea pedis (athlete's foot), tinea corpris (ringworm), tinea cruris (jock itch), tinea capitis (scalp ringworm), and onychomycosis (nail fungal infection — affecting approximately 10% of the general population); dermatophytes (Trichophyton, Microsporum, Epidermophyton) infect keratinized tissues (skin, hair, nails) — they are superficial infections; treatment: topical azoles (clotrimazole, miconazole, ketoconazole) or terbinafine for skin infections; systemic therapy (oral terbinafine, itraconazole, griseofulvin) for nail and hair infections; and the economic burden of dermatophyte infections is substantial — the global antifungal market exceeds $14 billion annually.
New antifungal drugs in development
The antifungal pipeline has been reinvigorated: fosmanogepix (a novel pro-drug of manogepix) — inhibits fungal inositol acyltransferase (Gwt1) → blocks GPI-anchored protein maturation → disrupts cell wall integrity; olorofim — inhibits dihydroorotate dehydrogenase (DHODH) → blocks pyrimidine synthesis → fungistatic activity against Aspergillus and other filamentous fungi; ibrexafungerp (the first orally available β-glucan synthase inhibitor — unlike echinocandins, which are IV-only) — approved for vulvovaginal candidiasis with ongoing trials for invasive candidiasis; and rezafungin (a long-acting echinocandin with an extended half-life allowing weekly dosing) — approved for candidemia. These new agents address critical unmet needs — oral administration, novel mechanisms, and activity against resistant organisms (Hoenigl et al., 2021, Nature Reviews Microbiology).
Climate change and emerging fungal threats
Climate change is creating new fungal disease threats: rising global temperatures may enable thermally adapted fungi to infect humans — Candida auris is hypothesized to have emerged as a human pathogen because of its ability to tolerate higher temperatures (environmental adaptation to warming conditions enabling mammalian infection); expanding geographic ranges of endemic mycoses — coccidioidomycosis (Valley fever) is moving northward in the United States as arid conditions expand; increasing frequency of natural disasters → disrupted environments → aerosolized fungal spores → outbreaks (coccidioidomycosis after California wildfires and earthquakes); and the "thermal restriction zone" hypothesis suggests that as environmental temperatures rise, more fungi will be able to grow at human body temperature (37°C) — potentially creating new human pathogens from previously non-pathogenic environmental fungi (Casadevall et al., 2019, mBio).
Antifungal drug interactions
Antifungal medications have clinically important drug interactions: azoles are potent inhibitors of cytochrome P450 enzymes (particularly CYP3A4, CYP2C9, CYP2C19) → increasing levels of: calcineurin inhibitors (tacrolimus, cyclosporine — critical in transplant patients), warfarin (increased bleeding risk), statins (rhabdomyolysis risk), benzodiazepines, and many other drugs; amphotericin B nephrotoxicity is potentiated by: other nephrotoxic drugs (aminoglycosides, vancomycin, cisplatin), volume depletion, and electrolyte imbalances; and echinocandins have relatively few drug interactions — one of their therapeutic advantages. Managing antifungal drug interactions in critically ill patients on multiple medications is one of the most challenging aspects of clinical infectious disease practice.
Antifungal susceptibility testing
Unlike bacterial susceptibility testing (which is highly standardized), antifungal susceptibility testing has historical challenges: the Clinical and Laboratory Standards Institute (CLSI) and the European Committee on Antimicrobial Susceptibility Testing (EUCAST) have established reference methods (broth microdilution); clinical breakpoints (the antibiotic concentration that predicts treatment response) have been established for Candida species and some Aspergillus species; MIC (minimum inhibitory concentration) values for azoles, echinocandins, and amphotericin B guide therapy — particularly for resistant organisms; and the emerging importance of antifungal resistance has made susceptibility testing increasingly routine in clinical microbiology laboratories — a shift from the historical practice of empiric antifungal therapy.
Fungal biofilms
Fungal biofilms — structured microbial communities attached to surfaces — present unique treatment challenges: Candida biofilms form on: central venous catheters, prosthetic valves, urinary catheters, joint prostheses, and other indwelling medical devices; biofilm organisms are dramatically more resistant to antifungals than planktonic (free-floating) organisms — often 100-1,000× higher MICs; the biofilm matrix (extracellular polysaccharides, proteins, lipids) physically shields organisms from drug penetration; and device-associated Candida infections often require device removal — antifungal therapy alone is frequently insufficient for biofilm-associated infections (Nett & Andes, 2016, Infectious Disease Clinics of North America).
The mycobiome
The human mycobiome — the fungal component of the microbiome — is an emerging research frontier: the gut mycobiome is dominated by Candida, Saccharomyces, and Malassezia species; mycobiome dysbiosis (altered fungal community composition) has been associated with: inflammatory bowel disease, asthma, allergic disease, and colorectal cancer; fungal-bacterial interactions in the microbiome may influence health outcomes — Candida overgrowth following antibiotic treatment disrupts the bacterial microbiome recovery; and understanding the mycobiome may reveal new therapeutic targets — and new concerns about the collateral effects of antifungal medications on the commensal fungal community.
Antifungal prophylaxis in high-risk patients
Antifungal prophylaxis is a critical component of care for immunocompromised patients: hematopoietic stem cell transplant recipients — fluconazole or micafungin prophylaxis reduces invasive candidiasis; posaconazole prophylaxis is recommended for patients with graft-versus-host disease (GVHD) or prolonged neutropenia — reducing invasive aspergillosis; solid organ transplant recipients — centers vary in prophylactic regimens based on local epidemiology and organ type (lung transplant recipients have the highest fungal infection risk); ICU patients — fluconazole prophylaxis in high-risk ICU patients remains controversial (reduces candidiasis but may promote azole-resistant Candida species); and HIV/AIDS patients — primary prophylaxis against Pneumocystis (TMP-SMX) and secondary prophylaxis against cryptococcal meningoencephalitis (fluconazole) have dramatically improved survival in the antiretroviral therapy era.
Antifungal therapeutic drug monitoring
Therapeutic drug monitoring (TDM) is important for several antifungals: voriconazole — highly variable pharmacokinetics (CYP2C19 polymorphisms cause dramatic interindividual variation): target trough concentration 1-5.5 μg/mL; subtherapeutic levels → treatment failure; supratherapeutic levels → neurotoxicity (visual hallucinations, encephalopathy), hepatotoxicity; posaconazole — oral absorption is variable (significantly improved with the delayed-release tablet formulation vs. oral suspension): target trough >1 μg/mL for prophylaxis, >1.25 μg/mL for treatment; itraconazole — variable absorption (requires acidic gastric pH): target trough >0.5 μg/mL; 5-flucytosine — narrow therapeutic index: target peak 50-100 μg/mL (above 100 → bone marrow suppression); and TDM-guided dosing has been associated with improved outcomes for voriconazole-treated patients.
Endemic mycoses
Unlike opportunistic fungi that primarily infect immunocompromised patients, endemic mycoses can cause disease in healthy individuals: Histoplasma capsulatum (histoplasmosis) — Ohio and Mississippi River valleys, Central America — inhaled from bat guano/soil → pulmonary or disseminated disease; Coccidioides immitis/posadasii (coccidioidomycosis/"Valley fever") — US Southwest, Mexico — inhaled from soil → pneumonia or disseminated disease; Blastomyces dermatitidis (blastomycosis) — Great Lakes, Ohio/Mississippi valleys — inhaled from soil → pulmonary or disseminated disease; Talaromyces marneffei (talaromycosis) — Southeast Asia — primarily in HIV/AIDS patients → disseminated disease; and Paracoccidioides brasiliensis (paracoccidioidomycosis) — Latin America — chronic progressive granulomatous disease.
Antifungal medications represent a small but critical pharmacological arsenal protecting against an entire kingdom of pathogens. With limited drug classes, emerging resistance (Candida auris, azole-resistant Aspergillus), expanding clinical populations at risk (immunosuppression, transplantation, ICU care), and climate change potentially creating new fungal threats — antifungal drug development and stewardship are among the most urgent priorities in infectious disease medicine.
Antifungal resistance mechanisms in detail
Understanding the molecular basis of antifungal resistance is critical: azole resistance in Candida: point mutations in ERG11 (encoding lanosterol 14α-demethylase) → reduced drug-target binding; upregulation of efflux pumps (CDR1/CDR2 — ABC transporters, and MDR1 — major facilitator superfamily); ERG3 mutations → alternative sterol synthesis pathways that bypass the azole-blocked step; and aneuploidy — increased copy number of chromosome 5 (containing ERG11 and TAC1 transcription factor); echinocandin resistance: point mutations in FKS1 and FKS2 (encoding β-1,3-glucan synthase) — hot spot mutations that reduce drug binding affinity; and amphotericin B resistance: extremely rare — may involve altered membrane sterol composition (reduced ergosterol content) — but this is potentially maladaptive (compromised membrane function) (Robbins et al., 2017, Nature Reviews Drug Discovery).
Mucormycosis: the black fungus
Mucormycosis deserves special attention as one of the most aggressive fungal infections: caused by Mucorales order fungi (Rhizopus, Mucor, Lichtheimia species); risk factors: uncontrolled diabetes (particularly with ketoacidosis), hematologic malignancy, solid organ transplant, trauma, and corticosteroid use; forms: rhinocerebral (most common in diabetic patients — begins in sinuses, rapidly invades orbit and brain), pulmonary, cutaneous, gastrointestinal, and disseminated; treatment: requires combination of surgical debridement (often radical — including orbital exenteration) and amphotericin B (the only reliably active antifungal — azoles and echinocandins have limited activity against Mucorales); mortality remains 40-80% depending on form and underlying condition; and the COVID-19 pandemic saw a dramatic surge in mucormycosis cases in India ("black fungus epidemic") — driven by corticosteroid use, diabetes, and immunosuppression (Jeong et al., 2019, Mycoses).
The world of antifungal medicine operates in a narrower therapeutic space than any other area of antimicrobial therapy — fewer drug classes, greater host similarity, emerging resistance, and expanding patient populations at risk. Every antifungal approved represents a molecular solution to the fundamental challenge of targeting a eukaryotic pathogen without destroying eukaryotic host cells.
The antifungal story is a story of limitations gracefully navigated — of pharmacologists finding molecular differences between fungal and human cells, exploiting those differences with four drug classes, and managing the complications that arise when treating one eukaryote with drugs that inevitably affect another eukaryote. Understanding antifungal medicine is understanding the art of selective toxicity at its most challenging.
Fungi have inhabited the Earth for over a billion years, evolving elaborate mechanisms for survival and adaptation. Our antifungal arsenal — developed over merely decades — must be as thoughtfully stewarded as our antibiotics, or we risk losing our ability to treat infections caused by organisms that have survived every mass extinction event in Earth's history.
The kingdom Fungi has been called the "forgotten kingdom" of infectious disease. As climate change, immunosuppression, and global travel expand the fungal threat landscape, antifungal medicine will need to evolve rapidly — with new drugs, better diagnostics, and wiser stewardship of our limited arsenal.